Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that it will host an investor webcast to discuss new data from the bioMUSE Natural History Study. The webcast is scheduled for May 30, 2024, in Australia and May 29, 2024, in the United States. The company's CEO, Dr. David Stamler, will present the study results, which will inform the endpoints for the ATH434-202 Phase 2 clinical trial. Key opinion leader Daniel Claassen, M.D., from Vanderbilt University, will also participate in the webcast. Dr. Claassen is the Principal Investigator of bioMUSE and the Coordinating Investigator of the ATH434-201 Phase 2 clinical trial. The event will provide an opportunity for investors to ask questions and engage with the company's leadership. Alterity Therapeutics is currently evaluating its lead asset, ATH434, in two Phase 2 clinical trials for Multiple System Atrophy and has a drug discovery platform focused on neurological diseases. The announcement was authorized by CEO David Stamler.

Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that it will host an investor webcast to discuss new data from the bioMUSE Natural History Study. The webcast is scheduled for May 30, 2024, in Australia and May 29, 2024, in the United States. The company's CEO, Dr. David Stamler, will present the study results, which will inform the endpoints for the ATH434-202 Phase 2 clinical trial. Key opinion leader Daniel Claassen, M.D., from Vanderbilt University, will also participate in the webcast. Dr. Claassen is the Principal Investigator of bioMUSE and the Coordinating Investigator of the ATH434-201 Phase 2 clinical trial. The event will provide an opportunity for investors to ask questions and engage with the company's leadership. Alterity Therapeutics is currently evaluating its lead asset, ATH434, in two Phase 2 clinical trials for Multiple System Atrophy and has a drug discovery platform focused on neurological diseases. The announcement was authorized by CEO David Stamler.